Wall Street's Wild New Stock Picks!

Wall Street's Fresh Holy Trinity of "WTF Is This Stock Smoking?" – October 3, 2026 Edition[1]

Back at it, you beautiful degenerates. Markets are still a beautiful mess—AI vapor, energy storage dreams, and franchise empires all getting the short-seller treatment like it's open season on hopium. I scoured the latest short-interest data (Sep 15 settlement vibes still dominating the tape) for three new names where the bears are stacking chips like it's a poker game they rigged, and the bulls are yelling "squeeze me daddy." No GRPN/SOUN/SERV/LCID/HTZ/CLSK repeats—just raw, divided chaos with shorts north of 35% screaming "prove me wrong." Here's the fresh holy trinity of "who the actual fuck knows?"

1. ONDS (Ondas Holdings): The Rail/Drone Tech Fever Dream

The Bull Case (We're the Autonomous Future on Tracks and in the Sky):
Bulls see a scrappy player in rail communications, drone systems, and critical infrastructure—think 5G-enabled rail safety, autonomous drones for inspection/delivery, and partnerships that could explode if adoption hits. Shorts are heavy (~40%+ float in recent scans), but any big contract win, regulatory tailwind, or "AI + drones = moon" narrative could trigger a violent squeeze. "The tech is real; execution is finally catching up" is the cope—scale the platform and watch revenue ramp while shorts get vaporized.[1]

The Bear Case (Vaporware on the Tracks—Another Speculative Burn):
Reality check: Years of losses, pre-revenue scale issues in competitive spaces, heavy cash burn, and a business model that screams "government contracts or bust." High shorts reflect the market's verdict—this thing has been promising the autonomous revolution forever without consistent delivery. One missed milestone, funding crunch, or macro slowdown and it's dilution city or worse. Rail drones? More like rail delusions.[2]

My First-Principles Breakdown:
Strip it to atoms: Critical infrastructure tech wins on reliability, integration, and real-world deployment—not just cool demos. ONDS has niche tech edges in rail comms and drones, but "scaling via partnerships" assumes flawless execution against bigger players with deeper pockets and proven track records. Shorts correctly price in execution and adoption risks in a capital-intensive game; bulls correctly price in asymmetric upside if rail modernization or drone regs accelerate. Classic high-vol binary—fun volatility, not a core position.

2. XPOF (Xponential Fitness): The Boutique Franchise Sweat Equity Gamble

The Bull Case (We're the Cockroach of Boutique Fitness—Unkillable Growth Machine):
Bulls hype the multi-brand franchise model (Club Pilates, CycleBar, etc.) as a scalable, asset-light way to ride the wellness boom—membership growth, international expansion, and "experience economy" tailwinds. Shorts piled on (~42%+ in scans), but any earnings beat, new brand launches, or consumer spending resilience could spark a squeeze. "Franchise economics are proven; we're just hitting scale" is the mantra—expand the empire and watch margins fatten while shorts eat their yoga mats.[1]

The Bear Case (Overleveraged Franchise Clown Car on Fire):
Reality bites: Franchise models can hide unit-level weakness, brutal competition from bigger players and at-home options, consumer fatigue post-pandemic, and debt-fueled growth that blows up in a slowdown. High shorts aren't random—they're the market saying "this growth story has cracks." One franchisee revolt, macro dip, or execution miss and it's write-downs or worse. Boutique fitness? More like boutique bankruptcy risk.[3]

My First-Principles Breakdown:
Fundamentally, fitness franchises live or die on unit economics, brand loyalty, and consumer discretionary spending. XPOF has a diversified brand portfolio and franchise leverage, but "scaling the empire" requires consistent same-store sales and low churn in a competitive, trend-driven space. Shorts flag structural risks in a post-hype wellness market; bulls flag optionality in a health-obsessed world. High-risk growth bet with squeeze lottery potential—trade the narrative, size accordingly.

3. RXRX (Recursion Pharmaceuticals): The AI Drug Discovery Hype Cycle

The Bull Case (We're the AI-Powered Pharma Revolution—Data Moat for Days):
Bulls see a pure-play AI/biotech disruptor using machine learning to slash drug discovery timelines and costs—massive datasets, partnerships with big pharma, and a pipeline that could deliver blockbusters. Shorts are aggressive (~35%+), setting up a moonshot on any positive trial data, deal announcement, or AI bull market continuation. "We're not another me-too biotech; we're the tech layer" is the rally cry—monetize the platform and shorts get left in the dust.[1]

The Bear Case (All Algorithm, No Molecules—Classic Biotech Burn Rate):
Reality: Pre-clinical heavy, massive cash burn, long clinical/regulatory timelines, competition from bigger AI-pharma players, and a valuation that assumes perfection no one has delivered. Shorts see through the hype—most of this is still speculative bets on data translating to approved drugs that could take years or flop. One failed trial or dilution wave and the AI-drug dream evaporates. Recursion? More like regression to the mean.[4]

My First-Principles Breakdown:
At core, drug discovery is a probability game of biology, chemistry, and capital—AI can accelerate screening but doesn't eliminate failure rates or regulatory walls. RXRX has a differentiated data/AI approach and early partnerships, but "platform scaling" assumes the tech edge survives real-world validation and competition. Shorts correctly flag the binary clinical risks and burn; bulls correctly flag the transformative upside if AI meaningfully bends the cost curve. High-volatility speculation—lottery ticket with real scientific intrigue.

Bottom Line (No Crystal Ball, Just Brutal Logic):
These three capture the current divided vibe: rail/drone tech gamble, fitness franchise expansion bet, and AI-biotech moonshot. The common thread? Sky-high skepticism via shorts, but real catalysts that could flip the script. Markets adore punishing uncertainty—and these names are marinated in it. Laugh at the chaos, size positions like your rent depends on it (or don't), and remember: this is entertainment with numbers. Your move, degenerates.

Sources for the terminally curious (verify this shit yourself): Recent short-interest trackers and screens (e.g., FindMyMoat, Benzinga, TheDesperateTrader) highlighting elevated levels in ONDS, XPOF, and RXRX; market commentary on the underlying sector debates. Always do your own digging—these are snapshots of a deranged market. Trade responsibly, or at least don't cry when it goes tits up.